Entero Healthcar Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,087 Cr +32.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
EH

Entero Healthcar

Q4 FY25Retailing

Entero Healthcar Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,339Cr
+29.5% YoY
−1.5% QoQ
Net profit
₹31Cr
+47.6% YoY
+6.9% QoQ
Margin
3.6%
+0.8 pp YoY
−0.1 pp QoQ
Price₹1,633
Market cap₹6.2K Cr
P/E48.0

The short version

Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).

From Entero Healthcar's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth.
  • FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate.
  • IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%.
  • Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores.
  • New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues.
  • Long-term plan includes doubling down on organic expansion via new pharmacies, hospitals, and increased wallet share.
  • Growth strategy balanced between organic growth and margin-accretive inorganic acquisitions.

2 more points from Entero Healthcar's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Entero Healthcar said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues.
  • Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities.
  • Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform.

2 more points from Entero Healthcar's call on capex

Create a free account to keep reading this call

Top-ranked in Retailing

Ranked on what management guided this quarter

Guidance-ranked
1Rentomojo
Rev 1Mar 3
2V2 Retail
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Entero Healthcar said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Discussion focuses on acquisitions, integration timelines, and revenue growth guidance.
  • Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner.
  • Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA.

2 more points from Entero Healthcar's call on order book

Create a free account to keep reading this call

Entero Healthcar — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Entero Healthcar Q4 FY25 results — key figures

Entero Healthcar Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue1,3391,034+29.5%1,359-1.5%
Operating profit (EBITDA)4929+69%50-2%
Operating margin3.6%2.8%+0.8 pp3.7%-0.1 pp
Profit before tax3714+164.3%39-5.1%
Net profit (PAT)3121+47.6%29+6.9%
EPS (₹)5.904.82+22.4%5.85+0.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.1K Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Retailing this season

  • Trent (Q4 FY25)

    GST): ₹17,624 crore (Page 6) . Key concall takeaways from Trent Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Baazar Style (Q4 FY25)

    Store additions planned around 40 to 50 stores in FY ’26, with 20% to 25% increase in store count. Key concall takeaways from Baazar Style Retail Ltd's Q4 FY25…

  • V2 Retail (Q4 FY25)

    Volume growth remains strong, with 43% growth in FY25, supported by increased store count and product acceptance. Key concall takeaways from V2 Retail's Q4…

  • FSN E-Commerce (Q4 FY25)

    Nykaa’s overall GMV grew 27% YoY in Q4 and 25% for the full year FY25, with net revenue growth at 24% YoY for the full year. Key concall takeaways from FSN…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Entero Healthcar and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Entero Healthcar Q4 FY25 results?

Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).

What is Entero Healthcar share price analysis?

Entero Healthcar currently shows a neutral. The stock trades at a P/E of 48.0 with a market cap of ₹6,196 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Entero Healthcar on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.